Corriente Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Corriente Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-71,115	Closed	-$10.1M	–	20
2021 Q2	$10.1M	Buy	+71,115	New	+$8.03M	5.43%	5
2021 Q1	–	Sell	-525,000	Closed	-$64.9M	–	19
2020 Q4	$64.9M	Buy	525,000 +225,000	+75%	+$29.6M	15.45%	2
2020 Q3	$29.2M	Buy	300,000 +152,500	+103%	+$19.1M	14.82%	2
2020 Q2	$23M	Sell	147,500 -42,500	-22%	-$6.46M	14.91%	2
2020 Q1	$27.4M	Sell	190,000 -2,000	-1%	-$386K	29.6%	1
2019 Q4	$39.3M	Buy	+192,000	New	+$35M	21.08%	2

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Corriente Advisors's RETA Position: Q3 2021 in Review

Corriente Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 71,115 shares — an estimated $10.1M sold.

Corriente Advisors first reported a position in RETA in Q4 2019 and held it in 6 quarters. The position peaked at $64.9M in Q4 2020. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

Corriente Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
Corriente Advisors sold 71,115 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $10.1M.
Corriente Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 6 quarters.
Corriente Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $64.9M in Q4 2020.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Corriente Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.